Week in Review: CStone Pharma, a Suzhou Oncology Company, Files for Hong Kong IPO

Deals and Financings   Suzhou 's CStone Pharma filed for a Hong Kong IPO to develop its portfolio of 14 oncology candidates including PD-1, PD-L1 and CTLA-4 antibodies; LG Chem Life Sciences of South Korea formed a nearly $1 billion three-candidate IO collaboration with Cue Biopharma, a Boston area IO company; Agilent Technologies closed its $250 million acquisition of ACEA Biosciences, a San Diego-Hangzhou company that makes cell analysis tools; I-Mab Biopharma of Tianjin in-licensed China rights to a novel checkpoint inhibitor from Germany 's MorphoSys in a $105 million agreement; NextCure of Maryland closed a $93 million series B financing led by China investors Hillhouse Capital and Quan Capital for next-gen immunomedicines; YITU Healthcare, a subsidiary of Shanghai artificial intelligence company YITU, raised nearly $15 million to apply AI to early cancer detection and screening; Shanghai Exuma Biotech, a subsidiary of Florida 's F1 Oncology, has been formed to develop F1 Oncology's proprietary CAR-T technologies in China ; Sinovant Sciences in-licensed China rights to BB3, a small molecule hepatocyte growth factor mimetic, developed by Angion Biomedica of New York State ; Trials and Approvals   Innovent Biologics of Suzhou reported its China NDA filing for IBI303, a biosimilar to Humira (adalimumab), was accepted; Generon ( Shanghai ) has been approved to start a China Phase I trial for A-319, a bi-specific antibody, in patients with B cell malignancies. Stock Symbols: (NSDQ: CUE) (NYSE: A) (FSE/NSDQ: MOR) (HK: 1801) Share this with colleagues: // //